Randomized controlled trials have shown that single drug treatment usually is not adequate to achieve blood pressure goal in most hypertensive patients [1] Received: February 20, 2008; Accepted: April 18, 2008 
rats, two-kidney, one-clip renovascular hypertensive rats (2K1C) and Lyon hypertensive rats (LH) were used as models for four different types of hypertension. SHR and LH are genetically hypertensive rats
and 2K1C and DOCA are models of experimentally induced hypertension. The 2K1C and SHR are models of angiotensin-dependent hypertension [6, 7] while LH and DOCA are models of low-renin hypertension [8] . 
Methods

Animals and chemicals
Preparation of 2K1C hypertensive rats
Male Sprague-Dawley rats weighing 180-200 g were anaesthetized with a combination of ketamine (40 mg/kg) and diazepam (6 mg/kg) . The right renal artery of each animal was isolated through a flank incision, as described previously [9] , and a silver clip (0.2-mm internal gap) was placed on the right renal artery. All animals were fed standard rat chow and tap water ad libitum. On day 21 after operation, blood pressures were measured by tail-cuff plethysmography and the rats with systolic blood pressure >150 mmHg were used for this study. Five weeks after placement of the clip, these rats received the treatment with different drugs.
Preparation of DOCA hypertensive rats
DOCA hypertensive rats were prepared as previously described [10] 
Intra-arterial blood pressure measurements
Systolic blood pressure, diastolic blood pressure and heart period were continuously recorded using previously described technique [11] . Briefly, rats were anaesthetized by a combination of ketamine (40 mg/kg) and diazepam (6 mg/kg 
Determination of baroreflex sensitivity
After a 4-hrs blood pressure recording, baroreflex sensitivity was measured in the conscious rat by using our previously described method [12] . A bolus of phenylephrine was injected to induce a blood pressure elevation. The dose of phenylephrine (5) (6) (7) (8) (9) (10) 
Probability sum test
To determine if the drugs were acting synergistically, we used the probability sum test (q test) [14] . Compared with the mean values in the control group of rats, treated rats with a decrease in blood pressure >20 mmHg were defined as responders and rats with a decrease in blood pressure 20 mmHg were defined as non-responders. For blood pressure
Fig. 1 Effects of long-term treatment with combination of amlodipine and atenolol on blood pressure (BP) and heart period (HP) in spontaneously hypertensive rats (SHR), Deoxycorticosterone Acetate-Salt rats (DOCA), 2-kidney, 1-clip rats (2K1C) and Lyon genetically hypertensive rats (LH)
. n = 10, mean ± S.D. *P < 0.05, **P < 0.01, ***P < 0.001 versus control. Figure 1 for abbreviations. *P < 0.05, **P < 0.01, ***P < 0.001 versus control. (Fig. 1) .
Fig. 2 Effects of long-term treatment with combination of amlodipine and atenolol on blood pressure variability (BPV), heart period variability (HPV) and Baroreflex sensitivity (BRS) in SHR, DOCA, 2K1C and LH. n = 10, mean ± S.D. See
variability, the criterion was 2 mmHg. The formula used is as follows: q = PA+B/(PA+PB-PAϫPB
Effects of combination therapy on blood pressure variability and baroreflex sensitivity
As shown in Figure 2, Table 2 and Figure 1 (Fig. 2) .
Effects of combination therapy on organ damage in four types of hypertensive rats
Some representative parameters of end-organ damage are shown in Figure 3 . (Fig. 3) . Tables 1 and 2. A number of medications are available for the treatment of hypertension, and all can reduce blood pressure to normal or nearnormal level [15, 16] [18] . In addition, blood pressure variability and baroreflex sensitivity were also studied and both were improved considerably by the combination therapy. There is increasing evidence showing that high blood pressure variability and low baroreflex sensitivity contribute to end-organ damage in hypertension [19] [20] [21] [22] [23] [24] [25] [26] [28] . DOCA model of hypertension is associated with markedly depressed plasma renin activity [29] . LH rats exhibit low renin; and it is possible that the enhanced renal sensitivity to angiotensin II plays a primary role in the pathogenesis of hypertension in this model [30] [1] . So, the choice of drug may be decided by tolerability rather than long-term safety or efficacy [31] . In our recent unpublished data, we have observed a synergism on blood pressure and blood pressure variability reduction and end-organ protection not only with the combination of atenolol and amlodipine, but also with the combination of atenolol and nitrendipine [32] ; hydrochlorothiazide and enalapril; amlodipine and candesartan; and amlodipine and irbesartan. Among these combinations we studied, it was found that the synergism of the combination between atenolol and amlodipine was the largest.
The parameters shown are LVW/BW (reflecting left ventricular hypertrophy), AW/length (reflecting aortic hypertrophy) and RCT/RMT and GSS (reflecting glomerular damage). We observed that atenolol alone reduced left ventricular hypertrophy, aortic hypertrophy and glomerular damage in SHR and 2K1C rats.
Amlodipine alone reduced aortic hypertrophy and glomerular damage in SHR and DOCA rats. When animals were treated with full dose combination, all four parameters of end-organ damage were markedly less (P < 0.01 or P < 0.001 versus monotherapy) in all four types of hypertension models. Most of the end-organ damage parameters were less pronounced when half dose of the combination was used
Synergism between amlodipine and atenolol
In conclusion, we have demonstrated a synergistic interaction between atenolol and amlodipine with regard as not only blood pressure reduction, but also blood pressure variability reduction, baroreflex sensitivity enhancement and end-organ protection. The synergism of atenolol and amlodipine was found in all models of hypertension.
